Pricing Log in Create free account

Altimmune, Inc. (ALT) vs Avalo Therapeutics, Inc. (AVTX)

Altimmune, Inc. and Avalo Therapeutics, Inc. are both Biotechnology companies. Altimmune, Inc. and Avalo Therapeutics, Inc. are of similar size ($396.8M and $388.8M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against −92.7%. Across the 15 metrics below, Altimmune, Inc. leads on 8 and Avalo Therapeutics, Inc. on 7.

Valuation

Metric ALT AVTX Biotechnology median
P/E n/m n/m 10.64
P/S 8,224.03 254.55 9.59
P/B 0.80 0.71 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m 0.78 0.65
EV/Sales 1,889.09 (57.24) 9.45
Earnings yield (38.24%) (65.26%) (34.69%)
Free cash flow yield (20.29%) (43.84%) (24.02%)

Profitability

Metric ALT AVTX Biotechnology median
Gross margin 100.00% 64.72% 65.59%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (28.87%) (36.27%) (51.96%)
Return on assets (25.58%) (32.50%) (46.06%)
Return on invested capital (34.30%) (118.21%) 0.00%

Growth

Metric ALT AVTX Biotechnology median
Revenue growth (TTM) 130.00% (92.65%) 4.59%
EPS growth (last fiscal year) 25.37% 72.07% 29.88%
Revenue growth, 5-year CAGR (65.33%) (61.19%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT AVTX Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 26.78 19.31 4.86
Net debt to EBITDA 2.49 1.36 1.01

Dividend

Metric ALT AVTX Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ALT AVTX Biotechnology median
Market cap 396.82m 388.82m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack